

# World Journal of *Clinical Oncology*

*World J Clin Oncol* 2024 May 24; 15(5): 576-666



**EDITORIAL**

- 576 Pembrolizumab autoimmune related diabetes: Moving forward, keep learning  
*Garcia JA, Alcaraz D, Holgado E, Couñago F*
- 580 Core needle biopsy for thyroid nodules assessment-a new horizon?  
*Dolidze DD, Covantsev S, Chechenin GM, Pichugina NV, Bedina AV, Bumbu A*
- 587 Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon  
*Lino-Silva LS, Martínez-Villavicencio SB, Rivera-Moncada LF*
- 591 Feasibility and limitations of combined treatment for lateral pelvic lymph node metastases in rectal cancer  
*Zheng YZ, Yan FF, Luo LX*
- 594 Navigating breast cancer brain metastasis: Risk factors, prognostic indicators, and treatment perspectives  
*Karthik J, Sehwat A, Kapoor M, Sundriyal D*
- 599 Colorectal cancer: Getting the perspective and context right  
*Lu JD, Tan KY*

**MINIREVIEWS**

- 603 Receptor tyrosine kinase-like orphan receptor 1: A novel antitumor target in gastrointestinal cancers  
*Wu ZL, Wang Y, Jia XY, Wang YG, Wang H*

**ORIGINAL ARTICLE****Retrospective Cohort Study**

- 614 Different types of tumor microvessels in stage I-IIIa squamous cell lung cancer and their clinical significance  
*Senchukova MA, Kalinin EA, Volchenko NN*

**Retrospective Study**

- 635 Human epidermal growth factor receptor 2 expression level and combined positive score can evaluate efficacy of advanced gastric cancer  
*Ma XT, Ou K, Yang WW, Cao BY, Yang L*

**Observational Study**

- 644 Impact of the economic crisis and drug shortage on Lebanese cancer patients' care  
*Eid D, Jabbour J, Moujaes E, Kourie HR, Safieddine M, Kattan J*

**Basic Study**

- 653** *In silico* prospective analysis of the medicinal plants activity on the CagA oncoprotein from *Helicobacter pylori*  
*Vieira RV, Peiter GC, de Melo FF, Zarpelon-Schutz AC, Teixeira KN*

**LETTER TO THE EDITOR**

- 664** Integrating disulfidptosis-related long noncoding RNAs in colorectal cancer prognosis: A path to precision medicine  
*Zhang SY*

**ABOUT COVER**

Peer Reviewer of *World Journal of Clinical Oncology*, Serghei Covantsev, BSc, MD, Doctor, Research Scientist, General Surgeon, Surgical Oncologist, Plastic Surgeon, Department of Research and Clinical Development & Department of Emergency Surgery №76, Botkin Hospital, Moscow 125284, Russia kovantsev.s.d@gmail.com

**AIMS AND SCOPE**

The primary aim of *World Journal of Clinical Oncology* (*WJCO*, *World J Clin Oncol*) is to provide scholars and readers from various fields of oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJCO* mainly publishes articles reporting research results and findings obtained in the field of oncology and covering a wide range of topics including art of oncology, biology of neoplasia, breast cancer, cancer prevention and control, cancer-related complications, diagnosis in oncology, gastrointestinal cancer, genetic testing for cancer, gynecologic cancer, head and neck cancer, hematologic malignancy, lung cancer, melanoma, molecular oncology, neurooncology, palliative and supportive care, pediatric oncology, surgical oncology, translational oncology, and urologic oncology.

**INDEXING/ABSTRACTING**

The *WJCO* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for *WJCO* as 2.8; IF without journal self cites: 2.8; 5-year IF: 3.0; Journal Citation Indicator: 0.36.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Yu-Qing Zhao*; Production Department Director: *Xu Guo*; Cover Editor: *Xu Guo*.

**NAME OF JOURNAL**

*World Journal of Clinical Oncology*

**ISSN**

ISSN 2218-4333 (online)

**LAUNCH DATE**

November 10, 2010

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Hiten RH Patel, Stephen Safe, Jian-Hua Mao, Ken H Young

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/2218-4333/editorialboard.htm>

**PUBLICATION DATE**

May 24, 2024

**COPYRIGHT**

© 2024 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/204>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

## Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon

Leonardo S Lino-Silva, Sabrina B Martínez-Villavicencio, Luisa Fernanda Rivera-Moncada

**Specialty type:** Oncology

**Provenance and peer review:**

Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's classification**

**Scientific Quality:** Grade C, Grade D

**Novelty:** Grade B, Grade C

**Creativity or Innovation:** Grade B, Grade C

**Scientific Significance:** Grade B, Grade B

**P-Reviewer:** Song T, China

**Received:** December 12, 2023

**Revised:** March 22, 2024

**Accepted:** April 17, 2024

**Published online:** May 24, 2024



**Leonardo S Lino-Silva, Sabrina B Martínez-Villavicencio, Luisa Fernanda Rivera-Moncada,** Department of Pathology Oncology, National Cancer Institute (Mexico), Tlalpan, Mexico City 14080, Mexico

**Corresponding author:** Leonardo S Lino-Silva, MD, MEd, PhD, Professor, Department of Department of Pathology Oncology, National Cancer Institute (Mexico), Av. San fernando 22, Sección XVI, Tlalpan, Mexico City 14080, Mexico. [saul.lino.sil@gmail.com](mailto:saul.lino.sil@gmail.com)

### Abstract

In this editorial, we comment on the article by Wang *et al.* This manuscript explores the potential synergistic effects of combining zanubrutinib, a novel oral inhibitor of Bruton's tyrosine kinase, with high-dose methotrexate (HD-MTX) as a therapeutic intervention for primary central nervous system lymphoma (PCNSL). The study involves a retrospective analysis of 19 PCNSL patients, highlighting clinicopathological characteristics, treatment outcomes, and genomic biomarkers. The results indicate the combination's good tolerance and strong antitumor activity, with an 84.2% overall response rate. The authors emphasize the potential of zanubrutinib to modulate key genomic features of PCNSL, particularly mutations in myeloid differentiation primary response 88 and cluster of differentiation 79B. Furthermore, the study investigates the role of circulating tumor DNA in cerebrospinal fluid for disease surveillance and treatment response monitoring. In essence, the study provides valuable insights into the potential of combining zanubrutinib with HD-MTX as a frontline therapeutic regimen for PCNSL. The findings underscore the importance of exploring alternative treatment modalities and monitoring genomic and liquid biopsy markers to optimize patient outcomes. While the findings suggest promise, the study's limitations should be considered, and further research is needed to establish the clinical relevance of this therapeutic approach for PCNSL.

**Key Words:** Primary central nervous system lymphoma; Zanubrutinib; Bruton's tyrosine kinase; Prognosis; Myeloid differentiation primary response 88 gene; Cluster of differentiation 79B gene

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** The combination of zanubrutinib with high-dose methotrexate shows promise as a therapeutic approach for primary central nervous system lymphoma (PCNSL). In this study involving 19 patients, the treatment demonstrated a notable 84.2% overall response rate with manageable adverse events. The presence of circulating tumor DNA in cerebrospinal fluid emerged as a potential tool for monitoring treatment response. These findings are optimistic, but research in larger patient groups is crucial to validate outcomes and assess long-term effects, especially in different molecular subtypes of PCNSL.

**Citation:** Lino-Silva LS, Martínez-Villavicencio SB, Rivera-Moncada LF. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon. *World J Clin Oncol* 2024; 15(5): 587-590

**URL:** <https://www.wjgnet.com/2218-4333/full/v15/i5/587.htm>

**DOI:** <https://dx.doi.org/10.5306/wjco.v15.i5.587>

## INTRODUCTION

In this editorial we comment on the article by Wang *et al*[1]. Primary central nervous system lymphoma (PCNSL) is a rare and aggressive subtype of non-Hodgkin lymphoma that primarily affects the central nervous system (CNS), including the brain, spinal cord, and eyes. This malignancy is distinct from systemic lymphomas as it arises and remains confined within the CNS, presenting unique diagnostic and therapeutic challenges. The majority of PCNSL cases are classified as diffuse large B-cell lymphoma (DLBCL), which is often associated with immunocompromised states such as individuals with human immunodeficiency virus/acquired immunodeficiency syndrome or those undergoing immunosuppressive therapy. PCNSL comprises approximately 2%-3% of all primary brain tumors, with an increasing incidence noted in recent years, particularly among the elderly and immunocompromised populations[2]. While the precise etiology remains unclear, immunosuppression, chronic inflammation, and infections such as with the Epstein-Barr virus have been suggested as potential risk factors[3].

PCNSL typically presents with nonspecific neurological symptoms including cognitive decline, focal neurological deficits, and seizure[4]. Ocular involvement, termed primary intraocular lymphoma, may occur concurrently, adding to the complexity of diagnosis[4]. Given the lack of pathognomonic clinical features, the definitive diagnosis often requires brain biopsy, as imaging findings may overlap with other brain lesions[4]. Prognosis in PCNSL is influenced by various factors. Advanced age, immunocompromised status, deep-seated lesions, and elevated lactate dehydrogenase levels at diagnosis are associated with poorer outcomes[5]. Additionally, the blood-brain barrier poses a challenge by limiting the efficacy of systemic treatments, contributing to the overall difficulty in managing PCNSL.

The primary treatment approach for PCNSL involves a combination of high-dose methotrexate (HD-MTX)-based chemotherapy and, in some cases, radiation therapy[6]. HD-MTX, which crosses the blood-brain barrier, forms the backbone of most treatment regimens. The addition of rituximab, an anti-cluster of differentiation 20 (CD20) monoclonal antibody, to chemotherapy protocols has improved outcomes and is now commonly incorporated into treatment strategies. For eligible patients, consolidation therapies such as autologous stem cell transplantation may be considered[6]. Current research in PCNSL focuses on identifying novel therapeutic strategies to enhance treatment efficacy and reduce toxicity. Immunotherapeutic approaches, including chimeric antigen receptor T-cell therapy, are being investigated for their potential in targeting lymphoma cells within the CNS[7]. Additionally, targeted therapies, such as Bruton's tyrosine kinase (BTK) inhibitors, are under exploration, offering promising avenues for future treatment modalities[8]. PCNSL represents a unique and challenging entity within the spectrum of lymphomas. Advances in diagnostic techniques, treatment modalities, and ongoing research are essential for improving outcomes in patients with this rare malignancy.

## BTK INHIBITORS AND LYMPHOMAS

Lymphomas, a heterogeneous group of blood cancers, often exhibit dysregulated signaling pathways that contribute to their pathogenesis. One key target for therapeutic intervention in lymphomas is BTK, a crucial enzyme in B-cell receptor signaling. In recent years, the development of BTK inhibitors has shown remarkable promise in the treatment of various lymphoid malignancies.

In the realm of lymphoma therapeutics, inhibitors targeting BTK have emerged as pivotal agents, with notable contenders including ibrutinib, acalabrutinib, and zanubrutinib.

Ibrutinib, which was granted approval for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma, has substantiated its efficacy through rigorous clinical trials[9]. Meanwhile, acalabrutinib, indicated for chronic lymphocytic leukemia and mantle cell lymphoma, has garnered attention for its distinctive selectivity and potency, a topic extensively elucidated in the study by Barf *et al*[10]. On a similar note, anubrutinib, specifically designed for adult mantle cell lymphoma, has undergone scrutiny in a phase 1 trial overseen by Tam *et al*[11], shedding light on both its safety profile and clinical effectiveness. Recent investigations have extended the application of BTK inhibitors to PCNSL. Zanubrutinib, in combination with HD-MTX, has emerged as a promising therapeutic avenue for newly diagnosed PCNSL[1]. A notable aspect of these studies involves the exploration of liquid biopsy techniques, particularly the use of circulating tumor DNA (ctDNA) in cerebrospinal fluid. This innovative approach has been proposed as a potential

monitoring tool for treatment response, providing valuable insights into disease surveillance.

BTK is an intracellular tyrosine kinase (non-membrane receptor) composed of 659 amino acids, with its gene located on chromosome Xq21.33-q22. BTK belongs to the tyrosine kinase family known as TEC. The domains that make up the structure of BTK are: a pleckstrin homology domain in the N-terminal region, which facilitates binding to lipid regions of phosphatidylinositol on the plasma membrane; a Src homology 2 (SH2) domain involved in protein-protein interaction binding to phosphorylated tyrosines; an SH3 domain with binding to proline-rich regions, and a C-terminal catalytic domain.

An important point to note is that pharmacological inhibition of BTK activity not only interferes with signaling through the B-cell receptor (BCR) but also with signals from the tumor microenvironment, such as those induced by chemokines and other survival factors for leukemic cells. Thus, BTK inhibitors promote the egress of the leukemic clone from its survival niches in lymphoid tissues, directing it towards cell death.

BTK inhibitors are classified as reversible or irreversible, depending on the site of inhibition on the protein. Irreversible inhibitors covalently bind to the cysteine residue at amino acid position 481 (kinase activity site), blocking adenosine triphosphate (ATP) binding; restoration of activity requires synthesis of new protein. Reversible inhibitors bind tightly to BTK but not covalently, resulting in transient ATP blockade. Irreversible or reversible BTK inhibitors potentially bind to other kinases with lower affinity, particularly those of the TEC family. This binding can lead to side effects and specific toxicity profiles, depending on which and how many kinases are inhibited. Therefore, increasing selectivity for BTK reduces the risk of toxicities.

While the progress in BTK inhibition for lymphomas is encouraging, challenges and questions persist. Further research is warranted to validate these findings in larger cohorts, assess long-term effects, and explore the efficacy of BTK inhibitors across molecular subtypes of lymphomas. The continuous trajectory of research in this domain is characterized by a relentless pursuit of optimizing therapeutic efficacy while minimizing adverse effects, underscoring the dynamic nature of this field.

---

## CLINICAL IMPLICATIONS

The study reports an overall response rate of 84.2%, with a 2-year progression-free survival of 75.6% and an overall survival of 94.1%. The safety profile is described, with a focus on hematological and non-hematological toxicities.

The efficacy results against genotoxic therapy are so successful that the end of chemo-immunotherapy in some neoplasms, including lymphoma, especially for CLL, is now a recognized postulate by leading research groups. Importantly, the manuscript explores the role of ctDNA in cerebrospinal fluid for disease surveillance and treatment response monitoring. Changes in ctDNA levels corresponded to radiographic responses in some patients, highlighting the potential utility of liquid biopsy profiling in PCNSL.

The treatments for PCNSL and DLBCL differ significantly. HD-MTX stands as the primary therapy for PCNSL. Zanubrutinib, a novel oral BTK inhibitor, holds promise as a therapeutic intervention targeting BCR and toll-like receptor signaling pathways. BTKs traverse the blood-brain barrier. This study investigates the oncological outcomes of a combined regimen of methotrexate with zanubrutinib. An advantage of this study is the molecular profiling of tumors, either from paraffin-embedded tissue, peripheral blood, or cerebrospinal fluid. Complete response was achieved in 11 patients, partial response in 5 patients, and disease progression in 3 patients. The overall response rate was 84.2%, with a 5-year overall survival of 94.1%, notably better in cases with a germinal center genotype. Perhaps the most significant point of this article is the observed survival rate, which surpasses the estimated rate in the literature for this lymphoma subtype, typically below 30%. The only potential confounder in this series and its results is the median age of patients (57 years), as age over 60 is an adverse prognostic factor in this lymphoma; however, this median age aligns with literature estimates. One should approach these findings with caution due to the retrospective nature of the study, where the selection criteria for the 19 patients treated with zanubrutinib are not precisely defined. Although inclusion and exclusion criteria were established, it remains unclear whether cases were consecutively recruited and the criteria for initiating treatment with zanubrutinib.

The study's findings have future implications, including the necessity for larger-scale prospective cohort studies and longer follow-up periods to validate the results, and the study underscores the potential of zanubrutinib as a frontline therapeutic regimen for PCNSL, paving the way for further research into optimizing treatment strategies.

---

## CONCLUSION

In summary, BTK inhibitors represent a transformative approach within the landscape of treatments for lymphomas. The evolving understanding of their mechanisms, coupled with developments of innovative applications in PCNSL and liquid biopsy monitoring, signifies a promising era in lymphoma therapeutics. Continued research endeavors are crucial to fully exploit the potential of BTK inhibitors for enhanced patient outcomes.

---

## FOOTNOTES

**Author contributions:** Lino-Silva LS, Martínez-Villavicencio S, and Rivera-Moncada LF contributed to this paper; Lino-Silva LS designed



the overall concept and outline of the manuscript; Martínez-Villavicencio S and Rivera-Moncada LF contributed to the discussion and design of the manuscript; Lino-Silva LS, Martínez-Villavicencio S, and Rivera-Moncada LF contributed to the writing and editing of the manuscript, and review of the literature.

**Conflict-of-interest statement:** All authors have no conflicts of interest to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** Mexico

**ORCID number:** Leonardo S Lino-Silva [0000-0002-7394-5123](https://orcid.org/0000-0002-7394-5123); Sabrina B Martínez-Villavicencio [0009-0005-6552-4133](https://orcid.org/0009-0005-6552-4133); Luisa F Rivera-Moncada [0009-0004-9329-7858](https://orcid.org/0009-0004-9329-7858).

**Corresponding Author's Membership in Professional Societies:** Mexican Society of Oncology (SMEO); Society of Latin-American Pathology (SLAP); European Network on Gastrointestinal Pathology (ENGIP).

**S-Editor:** Liu JH

**L-Editor:** A

**P-Editor:** Zhao YQ

## REFERENCES

- 1 Wang N, Chen FL, Pan L, Teng Y, Wei XJ, Guo HG, Jiang XM, Huang L, Liu SC, Liang ZL, Li WY. Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy. *World J Clin Oncol* 2023; **14**: 606-619 [PMID: [38179402](https://pubmed.ncbi.nlm.nih.gov/38179402/) DOI: [10.5306/wjco.v14.i12.606](https://doi.org/10.5306/wjco.v14.i12.606)]
- 2 Ferreri AJ, Cwynarski K, Pulezynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørlov JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. *Lancet Haematol* 2016; **3**: e217-e227 [PMID: [27132696](https://pubmed.ncbi.nlm.nih.gov/27132696/) DOI: [10.1016/S2352-3026\(16\)00036-3](https://doi.org/10.1016/S2352-3026(16)00036-3)]
- 3 Nayak L, Batchelor TT. Recent advances in treatment of primary central nervous system lymphoma. *Curr Treat Options Oncol* 2013; **14**: 539-552 [PMID: [23934511](https://pubmed.ncbi.nlm.nih.gov/23934511/) DOI: [10.1007/s11864-013-0252-6](https://doi.org/10.1007/s11864-013-0252-6)]
- 4 Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. *Neuro Oncol* 2019; **21**: 296-305 [PMID: [30418592](https://pubmed.ncbi.nlm.nih.gov/30418592/) DOI: [10.1093/neuonc/nyy192](https://doi.org/10.1093/neuonc/nyy192)]
- 5 Houillier C, Soussain C, Ghesquières H, Soubeyran P, Chinot O, Taillandier L, Lamy T, Choquet S, Ahle G, Damaj G, Agapé P, Moluçon-Chabrot C, Amiel A, Delwail V, Fabbro M, Jardin F, Chauchet A, Moles-Moreau MP, Morschhauser F, Casasnova O, Gressin R, Fornecker LM, Abraham J, Marolleau JP, Tempescul A, Campello C, Colin P, Tamburini J, Laribi K, Serrier C, Haioun C, Chebrek S, Schmitt A, Blonski M, Houot R, Boyle E, Bay JO, Oberic L, Tabouret E, Waultier A, Martin-Duverneuil N, Toutou V, Cassoux N, Kas A, Mokhtari K, Charlotte F, Alentorn A, Feuvret L, Le Garff-Tavernier M, Costopoulos M, Mathon B, Peyre M, Delgadillo D, Douzane H, Genet D, Aidaoui B, Hoang-Xuan K, Gyan E. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. *Neurology* 2020; **94**: e1027-e1039 [PMID: [31907289](https://pubmed.ncbi.nlm.nih.gov/31907289/) DOI: [10.1212/WNL.00000000000008900](https://doi.org/10.1212/WNL.00000000000008900)]
- 6 Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffiotti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F; International Extranodal Lymphoma Study Group (IELSG). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. *Lancet* 2009; **374**: 1512-1520 [PMID: [19767089](https://pubmed.ncbi.nlm.nih.gov/19767089/) DOI: [10.1016/S0140-6736\(09\)61416-1](https://doi.org/10.1016/S0140-6736(09)61416-1)]
- 7 Grommes C, DeAngelis LM. Primary CNS Lymphoma. *J Clin Oncol* 2017; **35**: 2410-2418 [PMID: [28640701](https://pubmed.ncbi.nlm.nih.gov/28640701/) DOI: [10.1200/JCO.2017.72.7602](https://doi.org/10.1200/JCO.2017.72.7602)]
- 8 Rubenstein JL, Gupta NK, Mannis GN, Lamarre AK, Treseler P. How I treat CNS lymphomas. *Blood* 2013; **122**: 2318-2330 [PMID: [23963042](https://pubmed.ncbi.nlm.nih.gov/23963042/) DOI: [10.1182/blood-2013-06-453084](https://doi.org/10.1182/blood-2013-06-453084)]
- 9 Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. *Nat Rev Cancer* 2018; **18**: 148-167 [PMID: [29348577](https://pubmed.ncbi.nlm.nih.gov/29348577/) DOI: [10.1038/nrc.2017.121](https://doi.org/10.1038/nrc.2017.121)]
- 10 Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, van Hoek M, de Zwart E, Mittag D, Demont D, Verkaik S, Krantz F, Pearson PG, Ulrich R, Kaptein A. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. *J Pharmacol Exp Ther* 2017; **363**: 240-252 [PMID: [28882879](https://pubmed.ncbi.nlm.nih.gov/28882879/) DOI: [10.1124/jpet.117.242909](https://doi.org/10.1124/jpet.117.242909)]
- 11 Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. *Blood* 2019; **134**: 851-859 [PMID: [31340982](https://pubmed.ncbi.nlm.nih.gov/31340982/) DOI: [10.1182/blood.2019001160](https://doi.org/10.1182/blood.2019001160)]





Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-3991568  
**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)  
**Help Desk:** <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

